Publisher
Springer Science and Business Media LLC
Reference170 articles.
1. Bournia, V. K. et al. All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015–2019. RMD Open https://doi.org/10.1136/rmdopen-2021-001694 (2021).
2. Mantero, J. C. et al. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial. Clin. Exp. Rheumatol. 36 (Suppl. 113), 146–149 (2018).
3. Campochiaro, C. & Allanore, Y. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years. Arthritis Res. Ther. 23, 155 (2021).
4. Gordon, J. K. & Domsic, R. T. Clinical trial design issues in systemic sclerosis: an update. Curr. Rheumatol. Rep. 18, 38 (2016).
5. Denton, C. P. Challenges in systemic sclerosis trial design. Semin. Arthritis Rheum. 49, S3–S7 (2019).
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献